Brief: Sigilon Therapeutics Announces Update On SIG-001 Phase 1/2 Study In Hemophilia A

Sigilon Therapeutics

29/11/2021 12:28

Nov 29 (Reuters) - Sigilon Therapeutics Inc  SGTX.O :
    * SIGILON THERAPEUTICS ANNOUNCES UPDATE ON SIG-001 PHASE 1/2
STUDY
IN HEMOPHILIA A
    * SIGILON THERAPEUTICS INC - FIBROSED SPHERES WERE OBSERVED
DURING
A RETRIEVAL PROCEDURE IN A PATIENT IN ITS PHASE 1/2 STUDY OF
SIG-001
    * SIGILON THERAPEUTICS INC - ALL THREE PATIENTS ENROLLED IN
SIG-001 TRIAL WILL CONTINUE TO BE FOLLOWED PER STUDY PROTOCOL
    * SIGILON THERAPEUTICS INC - PATIENT UNDERWENT A
LAPAROSCOPIC
PROCEDURE PRESCRIBED BY INVESTIGATOR TO RETRIEVE IMPLANTED
SPHERES
    * SIGILON THERAPEUTICS - UPON INSPECTION, WAS DETERMINED
THAT
SPHERES PLACED IN PATIENT HAD FIBROSED AND THAT CELLS WITHIN
SPHERES WERE NO LONGER VIABLE
    * SIGILON -  FINDINGS INVESTIGATING FIBROSED SPHERES IN
PATIENT
MAY HAVE IMPACT ON TIMING OF INITIATING DOSING OF PATIENTS IN
PHASE 1/2 TRIAL OF SIG-005

Source text for Eikon:  ID:nGNX493Rd9 
Further company coverage:  SGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))